BAYER AG
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Clinical Trials
2.6k
Trial Phases
5 Phases
Drug Approvals
280
Drug Approvals
Aflibercept Intravitreous Injection
- Product Name
- 艾力雅
- Approval Number
- 国药准字SJ20255004
- Approval Date
- May 19, 2025
Recombinant human interferon beta-1b for injection
- Product Name
- 倍泰龙
- Approval Number
- 国药准字SJ20130094
- Approval Date
- Aug 24, 2023
Iloprost Solution for Inhalation
- Product Name
- 万他维
- Approval Number
- 国药准字HJ20140940
- Approval Date
- Apr 25, 2023
Iloprost Solution for Inhalation
- Product Name
- 万他维
- Approval Number
- 国药准字HJ20140941
- Approval Date
- Apr 25, 2023
Iloprost Solution for Inhalation
- Product Name
- 万他维
- Approval Number
- 国药准字HJ20140939
- Approval Date
- Apr 25, 2023
Aflibercept Intravitreous Injection
- Product Name
- 艾力雅
- Approval Number
- 国药准字SJ20180010
- Approval Date
- Apr 10, 2023
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next
Clinical Trials
Distribution across different clinical trial phases (2060 trials with phase data)• Click on a phase to view related trials
BAY3401016; Biomarker Study Alport
- Conditions
- Alport Syndrome
- Interventions
- Other: Placebo
- First Posted Date
- 2025-10-08
- Last Posted Date
- 2025-10-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 60
- Registration Number
- NCT07211685
- Locations
- 🇺🇸
Nephrology Clinic at The Kirklin Clinic of UAB Hospital, Birmingham, Alabama, United States
🇺🇸The Peggy and Harold Katz Family Drug Discovery Center - Nephrology, Miami, Florida, United States
🇺🇸Center for Advanced Pediatrics - Nephrology, Atlanta, Georgia, United States
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
- Conditions
- Left Ventricular Systolic DysfunctionHeart Failure (Pediatric)
- Interventions
- First Posted Date
- 2025-09-25
- Last Posted Date
- 2025-09-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 117
- Registration Number
- NCT07192952
- Locations
- 🇺🇸
Children's Hospital Colorado - Anschutz Medical Campus - Cardiology, Aurora, Colorado, United States
🇺🇸Nemours Children's Hospital -Delaware, Wilmington, Delaware, United States
🇺🇸UF Health Shands Hospital - Pediatric Cardiology, Gainesville, Florida, United States
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
- Conditions
- Left Ventricular Systolic DysfunctionHeart Failure (Pediatric)
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-09-23
- Last Posted Date
- 2025-09-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 111
- Registration Number
- NCT07188805
- Locations
- 🇺🇸
Children's Hospital Colorado - Anschutz Medical Campus - Cardiology, Aurora, Colorado, United States
🇺🇸Nemours Children's Hospital -Delaware, Wilmington, Delaware, United States
🇺🇸UF Health Shands Hospital - Pediatric Cardiology, Gainesville, Florida, United States
A Study to Assess the Safety and Effects of Different Doses of an Investigational Drug, BAY 3389934, in Healthy Japanese Volunteers.
- Conditions
- Sepsis Associated Disseminated Intravascular Coagulation (DIC)
- Interventions
- Drug: Matching Placebo / Diluent
- First Posted Date
- 2025-09-16
- Last Posted Date
- 2025-10-03
- Lead Sponsor
- Bayer
- Target Recruit Count
- 16
- Registration Number
- NCT07176728
- Locations
- 🇯🇵
SOUSEIKAI Fukuoka Mirai Hospital, Fukuoka, Fukuoka Pref, Japan
An Observational Study to Learn More About the Safety of Rivaroxaban in Participants With Peripheral Arterial Disease Who Had Surgery to Improve Blood Flow to Their Legs
- Conditions
- Peripheral Arterial Disease (PAD)
- First Posted Date
- 2025-08-27
- Last Posted Date
- 2025-10-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1500
- Registration Number
- NCT07142655
- Locations
- 🇯🇵
Medical Data Vision Co., Ltd, Tokyo, Japan
- Prev
- 1
- 2
- 3
- 4
- 5
- 328
- Next
News
Irish Court Invalidates Bayer's Rivaroxaban Dosing Patent in €3.5 Billion Xarelto Challenge
The High Court of Ireland ruled that Bayer's patent protecting once-daily dosing of rivaroxaban (Xarelto) was invalid for lack of inventive step, affecting a product worth €3.5 billion globally in 2024.
Federal Circuit Upholds Generic Challenge to Bayer's Xarelto Patent Protection
The Federal Circuit rejected Bayer's appeal to dismiss a patent validity challenge from three generic drug makers targeting the blockbuster blood-thinning drug Xarelto.
Shilpa Medicare Receives EMA Approval for Generic Rivaroxaban Orodispersible Films
Shilpa Medicare Limited has secured European Medicine Agency approval for its generic Rivaroxaban Orodispersible Films, a bioequivalent alternative to Bayer's Xarelto tablets.
European Regulators Recommend Approval for Novo Nordisk's Weekly Diabetes Combination Therapy Kyinsu
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Novo Nordisk's once-weekly injectable diabetes treatment Kyinsu for adults with type 2 diabetes.
Advanced Liver Cancer Pipeline Shows Robust Growth with 50+ Companies Developing Novel Therapies
DelveInsight's 2025 pipeline report reveals over 50 active companies developing 52+ advanced liver cancer therapies, indicating strong industry commitment to addressing this challenging malignancy.
Alnylam Pharmaceuticals Joins Alliance for Genomic Discovery to Accelerate RNAi Drug Development
Alnylam Pharmaceuticals has joined the Alliance for Genomic Discovery as the ninth member, gaining access to a comprehensive clinical genomic database containing 250,000 whole-genomes to accelerate RNA interference therapeutic development.
AskBio Completes Enrollment in Phase 1 Gene Therapy Trial for Rare Neurological Disease MSA-P
AskBio has completed enrollment of 11 participants in its Phase 1 REGENERATE MSA-101 trial testing AB-1005 gene therapy for multiple system atrophy-parkinsonian type (MSA-P), a rare neurodegenerative disease affecting approximately 400,000 people worldwide.
Berlin Center for Gene and Cell Therapies Breaks Ground, Creating European Hub for Advanced Therapeutics
Bayer AG, Charité – Universitätsmedizin Berlin, and the Berlin Institute of Health officially began construction of the Berlin Center for Gene and Cell Therapies in September 2025, marking a significant milestone in European biotechnology infrastructure.
Australian Court Denies Preliminary Injunction Against Sandoz Aflibercept Biosimilar Launch
The Federal Court of Australia denied Regeneron and Bayer's preliminary injunction application against Sandoz's aflibercept biosimilars, allowing the launch of Afqlir and Enzeevu to proceed as planned.
Roivant Sciences Gains Orphan Drug Designation in Japan for Mosliciguat in Pulmonary Hypertension
Roivant Sciences' subsidiary Pulmovant received orphan drug designation from Japan's Ministry of Health, Labour and Welfare for mosliciguat, an inhaled soluble guanylate cyclase activator.